Overview

LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)

Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
Phase:
Phase 4
Details
Lead Sponsor:
UCB Pharma
Treatments:
Cetirizine
Desloratadine
Levocetirizine